Early investigations into N-cadherin antagonists, such as ADH-1 (adherex 1), have demonstrated their potential as anti-cancer agents, with promising results in clinical trials for melanoma [126] and indications of efficacy in ovarian cancer [127]. The gene discussed is CDH2; the disease is cancer.